亚洲非瓣膜性房颤患者达比加群较华法林急性肾损伤风险更低
基于台湾全国回顾性队列(2012-2013年),无慢性肾病(CKD)的NVAF患者中达比加群7702例、华法林7885例,有CKD史者分别为2256例和2089例。倾向评分加权后,达比加群较华法林与急性肾损伤(AKI)风险更低相关(无CKD HR 0.62,95%CI 0.49-0.77,p<0.001;CKD HR 0.56,95%CI 0.46-0.69,p<0.001)。
要点
- 亚洲NVAF患者中达比加群较华法林AKI风险更低。
- 无CKD者AKI风险HR 0.62,有CKD者HR 0.56。
- CHA2DS2-VASc高分患者华法林AKI年风险更高。
核心结论
- 在亚洲非瓣膜性房颤患者中,达比加群较华法林与更低的急性肾损伤风险相关。
研究设计与样本
- 台湾全国回顾性队列研究,纳入2012年6月1日至2013年12月31日患者。
- 无CKD史者达比加群7702例、华法林7885例;有CKD史者达比加群2256例、华法林2089例。
- 采用倾向评分加权法平衡组间协变量。
主要发现
- 无CKD队列中达比加群较华法林AKI风险HR 0.62(95%CI 0.49-0.77,p<0.001)。
- CKD队列中达比加群较华法林AKI风险HR 0.56(95%CI 0.46-0.69,p<0.001)。
- 无CKD者达比加群110mg与150mg每日两次分别占6762例(88%)和940例(12%)。
- CKD者达比加群110mg与150mg每日两次分别占2025例(90%)和231例(10%)。
- 随CHA2DS2-VASc评分从0/1增至6+,达比加群组AKI年发生率相对稳定(无CKD 1.87%-2.91%,CKD 7.31%-13.15%),华法林组明显升高(无CKD 2.00%-6.16%,CKD 6.82%-26.03%)。
关键数值与推荐
- 无CKD队列高CHA2DS2-VASc评分(≥4)者华法林年AKI风险显著高于达比加群。
- CKD队列高CHA2DS2-VASc评分(≥3)者华法林年AKI风险显著高于达比加群。
- 亚组分析中,达比加群低剂量或标准剂量、华法林初治或经治、有无糖尿病、CHA2DS2-VASc≥4或HAS-BLED≥3者,达比加群较华法林AKI风险均更低。
临床怎么用
- 亚洲NVAF患者选用达比加群可能较华法林降低AKI风险。
- 高CHA2DS2-VASc评分患者使用华法林时需更关注AKI风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether dabigatran is associated with a lower risk of acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown. OBJECTIVES: The authors compared the risk of AKI in Asians with NVAF who were prescribed dabigatran versus warfarin. METHODS: The authors analyzed patients enrolled in the Taiwan nationwide retrospective cohort study from June 1, 2012, to December 31, 2013. Dabigatran and warfarin were taken by 7,702 and 7,885 NVAF patients without a history of chronic kidney disease (CKD) and 2,256 and 2,089 NVAF patients with a history of CKD, respectively. A propensity-score weighted method was used to balance covariates across study groups. RESULTS: A total of 6,762 (88%) and 940 (12%) CKD-free patients and 2,025 (90%) and 231 (10%) CKD patients took dabigatran 110 mg and 150 mg twice daily, respectively. Dabigatran was associated with a lower risk of AKI than warfarin for either the CKD-free (hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.49 to 0.77; p < 0.001) or CKD (HR: 0.56; 95% CI: 0.46 to 0.69; p < 0.001) cohort. As the increment in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to 74 years, and female sex) increased from 0/1 to 6+ points, the incidence of AKI for the dabigatran group was relatively stable (1.87% to 2.91% per year for the CKD-free cohort; 7.31% to 13.15% per year for the CKD cohort) but increased obviously for patients taking warfarin for either CKD-free (2.00% to 6.16% per year) or CKD cohorts (6.82 to 26.03% per year). The warfarin group had a significantly higher annual risk of AKI than the dabigatran group for those with a high CHA2DS2-VASc score (≥4 for the CKD-free cohort and ≥3 for the CKD cohort). Subgroup analysis revealed that among dabigatran users, those taking either low-dose or standard-dose dabigatran, those with a warfarin-naïve or warfarin-experienced history, those with or without diabetes, and those with CHA2DS2-VASc ≥4 or HAS-BLED ≥3 (risk score based on hypertension, abnormal renal and liver function, stroke, prior major bleeding, labile international normalized ratios, age 65 years or older, drugs or alcohol usage history) all had a lower risk of AKI than those taking warfarin. CONCLUSIONS: Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than warfarin.
引用
- Chan YH, Yeh YH, See LC, et al. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. J Am Coll Cardiol. 2016. PMID: 27884245. doi:10.1016/j.jacc.2016.08.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。